10-Q: SeaStar Medical Faces Going Concern, Nasdaq Delisting Risk

SeaStar Medical Holding Corporation reported reduced net losses and increased cash, but faces substantial doubt about its ability to continue as a going concern and a Nasdaq minimum bid price non-compliance.

Summary

• Net loss for the nine months ended September 30, 2025, significantly decreased to $9.2 million from $20.4 million in the prior year period.
• Cash balance increased to $13.8 million as of September 30, 2025, from $1.8 million at December 31, 2024.
• Total stockholders' equity improved to $11.5 million as of September 30, 2025, from a deficit of $2.2 million at December 31, 2024.
• Revenue from QUELIMMUNE sales for the nine months ended September 30, 2025, was $814 thousand, up from $68 thousand in the same period of 2024, following FDA HDE approval in February 2024 and first commercial shipment in July 2024.
• Operating expenses for the nine months ended September 30, 2025, decreased by 24% to $9.9 million from $13.1 million in the prior year, driven by reductions in R&D and G&A costs.
• The company has an accumulated deficit of $148.8 million as of September 30, 2025.
• Management has concluded that cash on hand is insufficient to fund operations for at least 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• Nasdaq notified the company on July 31, 2025, of non-compliance with the $1.00 minimum bid price requirement, with a deadline of January 27, 2026, to regain compliance.
• The company has engaged in multiple equity offerings and warrant exercises, significantly increasing common shares outstanding to 34,096,420 as of September 30, 2025, from 5,977,246 at December 31, 2024.
• Two legal proceedings, a securities class action lawsuit and a stockholder derivative action, are ongoing, alleging material misstatements and breach of fiduciary duty.

Sentiment

Score: 3

Explanation: While the company has reduced its net loss and increased cash through significant capital raises, the persistent going concern warning, accumulated deficit, and Nasdaq delisting risk indicate a highly precarious financial position. The operational improvements are overshadowed by fundamental liquidity and solvency challenges.

Positives

• Net loss for the nine months ended September 30, 2025, decreased by 55% to $9.2 million compared to $20.4 million for the same period in 2024.
• Cash balance significantly increased to $13.8 million as of September 30, 2025, from $1.8 million at December 31, 2024, primarily due to financing activities.
• Stockholders' equity improved to $11.5 million as of September 30, 2025, from a deficit of $2.2 million at December 31, 2024.
• Net revenue from QUELIMMUNE sales grew substantially to $814 thousand for the nine months ended September 30, 2025, from $68 thousand in the prior year period, following FDA HDE approval and commercial launch.
• Total operating expenses decreased by $3.2 million, or 24%, for the nine months ended September 30, 2025, compared to the same period in 2024, reflecting cost reduction efforts.
• Net cash used in operating activities decreased to $9.5 million for the nine months ended September 30, 2025, from $11.3 million in the prior year period.
• The company has obtained FDA Breakthrough Device Designation (BDD) for six therapeutic indications for its SCD therapy, potentially accelerating approval pathways.
• No outstanding debt or notes payable obligations existed as of September 30, 2025, indicating improved balance sheet liquidity in this area.
• Certain employees and active Directors voluntarily forewent earned-but-unpaid bonuses and director fees, contributing to reduced general and administrative expenses.

Negatives

• Management has raised substantial doubt about the company's ability to continue as a going concern, as current cash is insufficient to fund operations for at least 12 months.
• The company has an accumulated deficit of $148.8 million as of September 30, 2025, indicating significant historical losses.
• Nasdaq notified the company on July 31, 2025, of non-compliance with the $1.00 per share minimum bid price requirement, risking potential delisting.
• Significant dilution has occurred due to multiple equity offerings and warrant exercises, with common shares outstanding increasing from 5.98 million to 34.10 million within nine months.
• The company relies heavily on future equity or debt financing, which may not be available on acceptable terms or at all.
• Warrants are unlikely to be exercised if the common stock trading price remains below their respective exercise prices, limiting potential cash proceeds.
• Two legal proceedings, a securities class action and a stockholder derivative action, are ongoing, alleging material misstatements and breach of fiduciary duty.
• The company has only recently begun limited commercial sales of QUELIMMUNE and has not yet generated sufficient revenue to fund its operations.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern, requiring additional financing to execute its business plan.
• Additional financing may not be available on acceptable terms, or at all, potentially forcing delays, reductions, suspensions, or cessation of development/commercialization efforts.
• Inability to raise additional capital could lead to a restructuring of operations or reorganization proceedings under U.S. bankruptcy or insolvency laws.
• The company is subject to risks common to early-stage medical technology companies, including new innovations, dependence on key personnel, protection of proprietary technology, and product liability.
• There is no assurance that the company's products or services will be accepted in the marketplace or that future products can be developed/deployed at acceptable cost and performance.
• Proposed U.S. legislation, including changes in tax law (e.g., new Section 899 for non-U.S. investors), may adversely impact the company and the value of its securities.
• The company's Common Stock may be delisted from Nasdaq if it does not maintain compliance with continued listing requirements, such as the $1.00 minimum bid price.
• Delisting from Nasdaq could reduce liquidity and market price of common stock, limit investor willingness, restrict access to public capital markets, and impair equity incentives for employees.
• The company's ability to generate future revenue depends on the successful roll-out of QUELIMMUNE and the successful development and commercialization of the adult SCD, which may not occur in a timely manner.

Future Outlook

The company expects to incur significant expenses for ongoing activities, including clinical development of its adult SCD for FDA approval, commercialization of QUELIMMUNE, and development of next-generation SCDs. If regulatory approval is obtained, the company plans to launch and commercialize its adult SCD in the U.S. and potentially international markets. It anticipates financing operations through equity or debt sales, credit facilities, collaborations, or grants until significant product revenue is generated. Research and development expenses are expected to increase, subject to funding, while general and administrative expenses are being reviewed for efficiencies despite anticipated increases with expansion.

Management Comments

• The company is principally engaged in the research, development, and commercialization of a platform medical device technology designed to modulate inflammation in various patient populations.
• QUELIMMUNE is the only FDA approved product for use in pediatric patients with AKI due to sepsis or a septic condition requiring kidney replacement therapy.
• We believe our technology has the potential to overcome limitations in existing anti-inflammatory treatments and address the challenge of selectively targeting activated neutrophils and monocytes.
• We believe our SCD therapy has the potential to transform the treatment of acute organ failure in the intensive care unit (ICU) and to improve organ function in patients with chronic kidney disease, certain cardiovascular diseases, and other serious inflammatory diseases.
• There is a substantial clinical need for safe and effective control of hyperinflammation and we believe that our first-in-class SCD therapy can address the large potential market of over one million patients each year that face life-threatening hyperinflammatory conditions, including organ failure and potential loss of life.
• The company is continuously reviewing research and development spend to ensure it is aligned with the company's objectives.
• The company is also in the process of reducing overall general and administrative spend, and identifying efficiencies.
• We believe our cash and cash equivalents are insufficient to meet our working capital and capital expenditure requirements for a period of at least twelve months from the date of our unaudited condensed consolidated financial statements... We believe that this raises substantial doubt about our ability to continue as a going concern.

Industry Context

SeaStar Medical operates in the medical technology industry, focusing on devices to modulate inflammation, particularly for acute kidney injury (AKI) and other inflammatory conditions. Its Selective Cytopheretic Device (SCD) therapy aims to address hyperinflammation and cytokine storms, a critical unmet need given the limitations of existing immunosuppressive or single-cytokine targeting therapies. The company's strategy involves leveraging FDA Breakthrough Device Designations to accelerate approval pathways and integrating its technology into existing hospital systems like CRRT and potentially dialysis systems, targeting a large patient population of over one million annually.

Management Changes

Corporate Governance

Legal Proceedings

• 2024 Securities Class Action Lawsuit (Wells v. SeaStar Medical Holding Corporation et al.): Filed July 5, 2024, alleging material misstatements/omissions regarding FDA approval timing and financial instrument recognition, culminating in a financial restatement. An amended complaint was filed March 4, 2025, and a motion to dismiss was filed May 5, 2025, which is currently pending. The lawsuit seeks compensatory damages.
• Stockholder Derivative Action (Lazo v. Schlorff, et. al.): Filed December 13, 2024, with factual allegations substantially similar to the Class Action. Claims against the CEO, former CFO, and certain board members for breach of fiduciary duty and Securities Exchange Act violations. The action seeks damages, restitution, and injunctive relief concerning corporate governance and internal controls. It was stayed January 30, 2025, pending the court's resolution of the motion to dismiss in the Class Action.

Stakeholder Impact

• Shareholders: Face significant potential dilution from ongoing equity raises, risk of delisting from Nasdaq impacting liquidity and share price, and uncertainty regarding recovery in potential bankruptcy proceedings. Legal proceedings also pose a risk to shareholder value.
• Employees: Some employees voluntarily forewent performance bonuses, indicating potential pressure on compensation. Management changes, such as the former CFO's termination, may affect team dynamics. Equity incentives could be impaired if the stock is delisted.
• Customers: Continued availability of the FDA-approved QUELIMMUNE product for pediatric AKI patients. Potential for future adult SCD product if clinical trials are successful and regulatory approval is obtained.
• Creditors: The company has reduced its outstanding debt obligations, with no notes payable outstanding as of September 30, 2025. A new short-term note payable was entered into post-period for D&O insurance, indicating ongoing financing needs.

Next Steps

• Continue clinical development of the adult Selective Cytopheretic Device (SCD) for FDA approval.
• Invest in the commercialization of QUELIMMUNE.
• Continue to develop next-generation SCDs.
• If regulatory approval is obtained, launch and commercialize the adult SCD in the U.S. market, including potential subsequent launches in key international markets.
• Raise additional capital through future debt or equity financing transactions, credit facilities, collaborations, or grants to fund operations.
• Address the Nasdaq minimum bid price requirement by January 27, 2026, to avoid delisting.
• Vigorously defend against the ongoing securities class action lawsuit.
• Monitor the stockholder derivative action, which is currently stayed pending resolution of the class action motion to dismiss.

Key Dates

Recommendation

The company faces severe going concern issues, explicitly stated by management, with insufficient cash to fund operations for the next 12 months. This fundamental liquidity challenge is compounded by an accumulated deficit of $148.8 million and a Nasdaq notification for non-compliance with the minimum bid price, which carries a significant delisting risk. While the company has reduced its net loss and increased cash through multiple dilutive capital raises, these actions highlight a desperate need for funding rather than sustainable operational profitability. The ongoing legal proceedings add further uncertainty. A seasoned investor would view the high financial risk, continuous dilution, and precarious listing status as strong reasons to sell or avoid the stock.

Keywords

SeaStar Medical, ICU, 10-Q, Quarterly Report, Medical Device, AKI, Acute Kidney Injury, QUELIMMUNE, SCD Therapy, Selective Cytopheretic Device, FDA Approval, HDE, Breakthrough Device Designation, Going Concern, Nasdaq Delisting, Equity Offering, Warrants, Clinical Trials, Hyperinflammation, Cytokine Storm, Financial Results